Why HCA Healthcare, Inc. (HCA) Stock Rose 5.6% on Aug 21, 2026
What happened
HCA Healthcare rose 3.64% to $421.07 following disclosure of institutional accumulation in recent SEC Form 13F filings released August 21, with major asset managers including Tocqueville Asset Management, Silvant Capital Management, and NewEdge Wealth taking or growing positions. MarketBeat consensus rating of 'Moderate Buy' with an average price target of $462.64 underscores a valuation gap above current trading levels, supported by Q2 fundamentals showing 8.7% year-over-year revenue growth to $20.23 billion.
HCA earnings on October 23, 2026 (consensus EPS estimate $6.78); monitor whether institutional accumulation sustains or reverses if uninsured patient volumes or payer mix headwinds worsen.
Frequently asked questions
Why did HCA Healthcare, Inc. (HCA) stock rise on Aug 21, 2026?
HCA Healthcare rose 3.64% to $421.07 following disclosure of institutional accumulation in recent SEC Form 13F filings released August 21, with major asset managers including Tocqueville Asset Management, Silvant Capital Management, and NewEdge Wealth taking or growing positions. MarketBeat consensus rating of 'Moderate Buy' with an average price target of $462.64 underscores a valuation gap above current trading levels, supported by Q2 fundamentals showing 8.7% year-over-year revenue growth to $20.23 billion.
How much did HCA stock rise on Aug 21, 2026?
HCA rose 5.6% during the Aug 21, 2026 trading session.